|
2024
|
Invention
|
Chimeric papillomavirus l1 protein.
The present invention relates to chimeric papilloma virus L1... |
|
2023
|
Invention
|
Preparation and use of recombinant five-component sars-cov-2 trimer protein vaccine capable of in... |
|
|
Invention
|
Preparation and use of recombinant multicomponent sars-cov-2 trimeric protein vaccine capable of ... |
|
2022
|
Invention
|
Preparation and application of recombinant multivalent novel coronavirus trimer protein vaccine c... |
|
|
Invention
|
Method for improving immunogenicity/antigenic trimer stability of ecd antigen of sars-cov-2 mutan... |
|
|
G/S
|
Vaccines; medicines for human purpose, namely pharmaceutical preparations for the treatment of ge... |
|
|
G/S
|
Vaccines; medicines for human purposes; biological
preparations for medical purposes; biological... |
|
|
G/S
|
Vaccines; medicines for human purpose, namely, pharmaceutical preparations for the treatment of g... |
|
|
Invention
|
Humanized anti-il17a antibody and application thereof.
The present invention belongs to the fiel... |
|
|
Invention
|
Multiple-variable dosage regimen for the treatment of cancers with high expression of egfr.
The ... |
|
|
Invention
|
Polyvalent immunogenicity composition for human papillomavirus.
The present invention relates to... |
|
|
Invention
|
Chimeric papilloma virus l1 protein. The present invention relates to chimeric papilloma virus L1... |
|
|
Invention
|
Humanized anti-vegf monoclonal antibody. The present invention belongs to the field of tumor immu... |
|
|
Invention
|
Humanized anti-vegf antibody fab fragment and use thereof.
The present invention belongs to the ... |
|
|
Invention
|
Stable formulation of human papillomavirus virus-like particle vaccine.
Provided is a stable for... |
|
|
Invention
|
Stable preparation of human papillomavirus virus-like particle vaccine. Provided is a stable prep... |
|
2021
|
G/S
|
vaccines; medicines for human purpose, namely, pharmaceutical preparations for the treatment of g... |
|
|
Invention
|
Method for improving immunogenicity by using glyco-coronavirus rbd antigen conjugate. A method fo... |
|
|
G/S
|
Vaccines; biological preparations for medical purposes; biological preparations for the treatment... |
|
|
G/S
|
Vaccines; medicines for human purposes, namely medicines for the treatment of eye diseases and me... |
|
|
G/S
|
Vaccines; medicines for human purposes; biological preparations for medical purposes; biological ... |
|
|
Invention
|
Method for reducing viral ade effect. Provided is a method for reducing a viral ADE effect. The m... |
|
|
Invention
|
Humanized anti-pd-1 antibody and the use thereof. The present disclosure provides a recombinant h... |
|
|
Invention
|
Stable formulation for recombinant anti-pd-1 monoclonal antibody.
Provided is a stable formulati... |
|
|
Invention
|
Stable formulation for recombinant anti-pd-1 monoclonal antibody. Provided is a stable form... |
|
|
Invention
|
Stable formulation for recombinant anti-pd-1 monoclonal antibody. Provided is a stable formulatio... |
|
|
Invention
|
Method for enhancing immunogenicity of antigen by forming fc fragment fusion protein glycoconjuga... |
|
|
Invention
|
Method for enhancing immunogenicity of protein/peptide antigen by means of forming fusion protein... |
|
|
Invention
|
Method for improving immunogenicity of protein/peptide antigen.
Disclosed is a method for improv... |
|
|
Invention
|
Method for improving immunogenicity of protein/peptide antigen. Disclosed is a method for improvi... |
|
|
Invention
|
Tgfßr2 extracellular domain truncated molecule, fusion protein of tgfßr2 extracellular domain tru... |
|
|
Invention
|
Tgfbr2 extracellular domain truncated molecule, fusion protein of tgfbr2 extracellular domain tru... |
|
|
Invention
|
Sars-cov-2 neutralizing antibody and preparation and use thereof. The present invention belongs t... |
|
|
Invention
|
Tgfβr2 extracellular domain truncated molecule, fusion protein of tgfβr2 extracellular domain tru... |
|
|
Invention
|
Preparation and application of cross-neutralizing antibody of sars-cov-2 and sars-cov. Involved i... |
|
2020
|
Invention
|
Humanized anti-tnfα antibody and use thereof. Provided are a humanized monoclonal antibody that b... |
|
|
Invention
|
Humanized anti-il17a antibody and use thereof. Provided are a humanized monoclonal antibody bindi... |
|
|
Invention
|
Polyvalent immunogenicity composition for human papillomavirus. Disclosed is a polyvalent human p... |
|
|
Invention
|
Chimeric papillomavirus l1 protein. The present invention relates to a chimeric papillomavirus L1... |
|
|
Invention
|
Humanized anti-vegf fab antibody fragment and use thereof. The present invention relates to the f... |
|
|
Invention
|
Chimeric human papillomavirus type 51 l1 protein. A chimeric human papillomavirus (HPV) type 51 L... |
|
|
Invention
|
Humanized anti-vegfr2 antibody and application thereof. Provided is a humanized anti-VEGFR2 antib... |
|
|
Invention
|
Chimeric human papillomavirus type 16 l1 protein. A chimeric human papillomavirus type 16 L1 prot... |
